[Takumi Ito] Establishment of Metabolite-based Ubiquitin Ligase Control Engineering

PRESTO Researcher

Takumi Ito

Takumi Ito

Department of Nanoparticle Translational Research, Tokyo Medical University
Associate Professor

Outline

Cereblon is a ligand-binding E3 ubiquitin ligase, which we originally discovered as the primary target of thalidomide. This study focuses on the metabolite-binding activity of cereblon. I aim to elucidate the role of cereblon in metabolic pathways and the mechanism of control of cereblon. My findings will contribute towards the establishment of “Ubiquitin Ligase Control Engineering”, which uses specific drugs to rapidly degrade proteins of interest.

Quick Access

Quick Access

 News

arrow On-going

arrow Completed

Program

  • CREST
  • PRESTO
  • ACT-I
  • ERATO
  • ACT-C
  • ACCEL
  • ALCA
  • RISTEX
Finish programs
  • Pamphlet
  • ProjectDB
  • GlobalActivity
  • Diversity-EN
  • OS_Policy-EN
  • Question-E